We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+47.65%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$600M
AUM Growth
+$162M
Cap. Flow
+$3.3M
Cap. Flow %
0.55%
Top 10 Hldgs %
72.6%
Holding
57
New
6
Increased
11
Reduced
18
Closed
13

Top Buys

Rank Stock Value
1
ARVN icon
Arvinas
ARVN
+$18.3M
2
CDXS icon
Codexis
CDXS
+$16.4M
3
LQDA icon
Liquidia Corp
LQDA
+$15M
4
DNA icon
Ginkgo Bioworks
DNA
+$8.22M
5
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$3.51M

Top Sells

Rank Stock Value
1
CPRX
Catalyst Pharmaceutical
CPRX
+$9.78M
2
FDMT icon
4D Molecular Therapeutics
FDMT
+$7.26M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$7.19M
4
CYTK icon
Cytokinetics
CYTK
+$6.87M
5
NTLA icon
Intellia Therapeutics
NTLA
+$4.88M

Sector Composition

Rank Sector Weight
1 Healthcare 98.64%
2 Miscellaneous 1.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PMVP icon
51
PMV Pharmaceuticals
PMVP
$66.3M
– –
-475,000
Closed -$770K
SVRA icon
52
Savara
SVRA
$1.13B
– –
-714,960
Closed -$2.88M
VSTM icon
53
Verastem
VSTM
$668M
– –
-915,000
Closed -$2.73M
VTYX
54
DELISTED
Ventyx Biosciences
VTYX
– –
-1,190,000
Closed -$2.75M
OKUR
55
OnKure Therapeutics
OKUR
$155M
– –
-16,500
Closed -$249K
1 2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q3 2024 Portfolio in Review

As of Q3 2024, Opaleye Management held 57 positions worth $600M, up 37% from $438M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Opaleye Management's Q3 2024 filing shows 6 new, 11 increased, 18 reduced and 13 closed positions. Its largest new stake was Ginkgo Bioworks: 820,202 shares worth $6.68M. The largest sale was Catalyst Pharmaceutical, an estimated $9.78M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Miscellaneous.

  • Opaleye Management's largest Q3 2024 buy was Ginkgo Bioworks: 820,202 shares worth $6.68M.
  • Opaleye Management added most to Arvinas in Q3 2024, an estimated $18.3M increase.
  • Opaleye Management's biggest Q3 2024 reduction was Catalyst Pharmaceutical, cutting an estimated $9.78M.
  • Opaleye Management fully exited 4D Molecular Therapeutics in Q3 2024, selling an estimated $7.26M.
  • Opaleye Management's ten largest holdings make up 73% of its $600M portfolio in Q3 2024.
  • Opaleye Management opened 6 new positions and closed 13 in Q3 2024.
  • Opaleye Management's portfolio value rose 37% quarter-over-quarter to $600M.

Based on Opaleye Management's 13F filing for Q3 2024, filed 14 Nov 2024.